AstraZeneca and the federal government are miles apart on what a federal judge should do next in the company's 340B contract pharmacy lawsuit.

DOJ and AstraZeneca Far Apart on How Company’s Lawsuit Should Proceed

Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to honor 340B contract pharmacy arrangements.

U.S. Chief Judge Leonard Stark of the District of Delaware ruled on June 16 Congress was silent about the role that contract pharmacies may play in purchases of 340B drugs, and “there is more than one permissible interpretation of the statute.” He ordered the two sides to report to him by yesterday on what relief AstraZeneca is entitled to in light of his ruling, and how the case should proceed, if at all.

Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to honor 340B contract pharmacy arrangements.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report